Hospital Acquired Infection Control Industry Will Grow Fastest in Asia-Pacific

The hospital-acquired infection control market will touch USD 34,909.7 million by 2030, driven at a rate of 1.6%. The industry advance will be powered by the growing count of surgical procedures, increasing consciousness of environmental and personal hygiene, and rising chronic disease prevalence.

To learn more about this report: https://bit.ly/3WKNhmN

All patients who are hospitalized are vulnerable to contracting a nosocomial infection. Young children, the aged, and people with a weak immune system are more vulnerable to HAIs than others.

Thus, disinfection is a popular procedure, with an over 68% market share in the past, with hospitals trying to lower the rates of HAIs. HAI symptoms can appear in two–three days after a patient's hospital admission and continue for up to 10 days post discharge. For preventing these infections, the acceptance of disinfection is on the rise. Some widely used disinfectants for preventing the spread of nosocomial infections are glutaraldehyde, formaldehyde, and hydrogen peroxide.

Recently, a drastic rise in the occurrence of neurological ailments, traumatic wounds, and CVDs and the introduction of cutting-edge surgical technologies, to manage and treat them, have been observed. As a result of these events, HAI control product demand is witnessing growth. For example, people suffering from neurological infections or accidents every year number nearly 20 million, approximately 14 million of whom need surgery.

Therefore, north America dominated the hospital-acquired infection control market, with a 35% revenue share, as stated by P&S Intelligence. This is because of the increase in the elderly population, the surge in the incidence of chronic diseases and HAIs, and the existence of prominent market players. For example, in the U.S., the population of people more than 65 years is nearly 45 million, and this number will reach more than 80 million by 2050.

Furthermore, the incidence of HAIs in the continent is extremely high. At hospitals in the U.S., the incidence of HAIs is above 1.5 million, and 100,000 people die of them each year.

APAC will grow the fastest in the years to come. In developing and underdeveloped nations, the requirement for HAI control solutions is on the rise on account of the increasing count of patients and economic development.

Moreover, the acceptance of cutting-edge medical equipment is snowballing with the augmentation in governments’ spending on healthcare sector, which is primarily being seen in a rise in the count of community, primary-care, secondary-care, and tertiary-care medical centers. Further, these nations lack the resources and awareness required to control HAIs, which makes the region a key opportunity area for market players.

It is because of the increasing number of surgical procedures that the demand for hospital-acquired infection control will increase even further in the years to come.